ArticleInvestigational new drugs2013

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer.

Glen J Weiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.